198 related articles for article (PubMed ID: 12950678)
1. Histamine inhibits neutrophil NADPH oxidase activity triggered by the lipoxin A4 receptor-specific peptide agonist Trp-Lys-Tyr-Met-Val-Met.
Betten A; Dahlgren C; Hermodsson S; Hellstrand K
Scand J Immunol; 2003 Sep; 58(3):321-6. PubMed ID: 12950678
[TBL] [Abstract][Full Text] [Related]
2. The synthetic chemoattractant Trp-Lys-Tyr-Met-Val-DMet activates neutrophils preferentially through the lipoxin A(4) receptor.
Dahlgren C; Christophe T; Boulay F; Madianos PN; Rabiet MJ; Karlsson A
Blood; 2000 Mar; 95(5):1810-8. PubMed ID: 10688842
[TBL] [Abstract][Full Text] [Related]
3. The mechanism for activation of the neutrophil NADPH-oxidase by the peptides formyl-Met-Leu-Phe and Trp-Lys-Tyr-Met-Val-Met differs from that for interleukin-8.
Fu H; Bylund J; Karlsson A; Pellmé S; Dahlgren C
Immunology; 2004 Jun; 112(2):201-10. PubMed ID: 15147563
[TBL] [Abstract][Full Text] [Related]
4. The peptide Trp-Lys-Tyr-Met-Val-D-Met activates neutrophils through the formyl peptide receptor only when signaling through the formylpeptide receptor like 1 is blocked. A receptor switch with implications for signal transduction studies with inhibitors and receptor antagonists.
Karlsson J; Fu H; Boulay F; Bylund J; Dahlgren C
Biochem Pharmacol; 2006 May; 71(10):1488-96. PubMed ID: 16549058
[TBL] [Abstract][Full Text] [Related]
5. Differential signaling of formyl peptide receptor-like 1 by Trp-Lys-Tyr-Met-Val-Met-CONH2 or lipoxin A4 in human neutrophils.
Bae YS; Park JC; He R; Ye RD; Kwak JY; Suh PG; Ho Ryu S
Mol Pharmacol; 2003 Sep; 64(3):721-30. PubMed ID: 12920210
[TBL] [Abstract][Full Text] [Related]
6. The synthetic peptide Trp-Lys-Tyr-Met-Val-Met-NH2 specifically activates neutrophils through FPRL1/lipoxin A4 receptors and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2.
Christophe T; Karlsson A; Dugave C; Rabiet MJ; Boulay F; Dahlgren C
J Biol Chem; 2001 Jun; 276(24):21585-93. PubMed ID: 11285256
[TBL] [Abstract][Full Text] [Related]
7. The non-steroidal anti-inflammatory drug piroxicam blocks ligand binding to the formyl peptide receptor but not the formyl peptide receptor like 1.
Stenfeldt AL; Karlsson J; Wennerås C; Bylund J; Fu H; Dahlgren C
Biochem Pharmacol; 2007 Oct; 74(7):1050-6. PubMed ID: 17692291
[TBL] [Abstract][Full Text] [Related]
8. Phagocyte activation by Trp-Lys-Tyr-Met-Val-Met, acting through FPRL1/LXA4R, is not affected by lipoxin A4.
Christophe T; Karlsson A; Rabiet MJ; Boulay F; Dahlgren C
Scand J Immunol; 2002 Nov; 56(5):470-6. PubMed ID: 12410796
[TBL] [Abstract][Full Text] [Related]
9. Identification of peptides that antagonize formyl peptide receptor-like 1-mediated signaling.
Bae YS; Lee HY; Jo EJ; Kim JI; Kang HK; Ye RD; Kwak JY; Ryu SH
J Immunol; 2004 Jul; 173(1):607-14. PubMed ID: 15210823
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil NADPH-oxidase activation by an annexin AI peptide is transduced by the formyl peptide receptor (FPR), whereas an inhibitory signal is generated independently of the FPR family receptors.
Karlsson J; Fu H; Boulay F; Dahlgren C; Hellstrand K; Movitz C
J Leukoc Biol; 2005 Sep; 78(3):762-71. PubMed ID: 15951351
[TBL] [Abstract][Full Text] [Related]
11. PKC-delta controls the fMLF-induced overproduction of superoxide by neutrophils.
Matron C; Chakravarti A; Allaeys I; Poubelle PE
Free Radic Biol Med; 2010 Jan; 48(2):207-15. PubMed ID: 19854263
[TBL] [Abstract][Full Text] [Related]
12. Low-affinity receptor-mediated induction of superoxide by N-formyl-methionyl-leucyl-phenylalanine and WKYMVm in IMR90 human fibroblasts.
Ammendola R; Russo L; De Felice C; Esposito F; Russo T; Cimino F
Free Radic Biol Med; 2004 Jan; 36(2):189-200. PubMed ID: 14744631
[TBL] [Abstract][Full Text] [Related]
13. The synthetic peptide Trp-Lys-Tyr-Met-Val-D-Met is a potent chemotactic agonist for mouse formyl peptide receptor.
He R; Tan L; Browning DD; Wang JM; Ye RD
J Immunol; 2000 Oct; 165(8):4598-605. PubMed ID: 11035102
[TBL] [Abstract][Full Text] [Related]
14. The N-formylpeptide receptor (FPR) and a second G(i)-coupled receptor mediate fMet-Leu-Phe-stimulated activation of NADPH oxidase in murine neutrophils.
Lavigne MC; Murphy PM; Leto TL; Gao JL
Cell Immunol; 2002; 218(1-2):7-12. PubMed ID: 12470609
[TBL] [Abstract][Full Text] [Related]
15. Reconstitution of chemotactic peptide-induced nicotinamide adenine dinucleotide phosphate (reduced) oxidase activation in transgenic COS-phox cells.
He R; Nanamori M; Sang H; Yin H; Dinauer MC; Ye RD
J Immunol; 2004 Dec; 173(12):7462-70. PubMed ID: 15585872
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Trp-Nle-Tyr-Met as a novel agonist for human formyl peptide receptor-like 1.
Wan HX; Zhou C; Zhang Y; Sun M; Wang X; Yu H; Yang X; Ye RD; Shen JK; Wang MW
Biochem Pharmacol; 2007 Jul; 74(2):317-26. PubMed ID: 17517377
[TBL] [Abstract][Full Text] [Related]
17. Utilization of two seven-transmembrane, G protein-coupled receptors, formyl peptide receptor-like 1 and formyl peptide receptor, by the synthetic hexapeptide WKYMVm for human phagocyte activation.
Le Y; Gong W; Li B; Dunlop NM; Shen W; Su SB; Ye RD; Wang JM
J Immunol; 1999 Dec; 163(12):6777-84. PubMed ID: 10586077
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporin H, Boc-MLF and Boc-FLFLF are antagonists that preferentially inhibit activity triggered through the formyl peptide receptor.
Stenfeldt AL; Karlsson J; Wennerås C; Bylund J; Fu H; Dahlgren C
Inflammation; 2007 Dec; 30(6):224-9. PubMed ID: 17687636
[TBL] [Abstract][Full Text] [Related]
19. Lipoxin A(4) metabolites/analogues from two commercial sources have no effects on TNF-alpha-mediated priming or activation through the neutrophil formyl peptide receptors.
Forsman H; Dahlgren C
Scand J Immunol; 2009 Oct; 70(4):396-402. PubMed ID: 19751275
[TBL] [Abstract][Full Text] [Related]
20. NADPH-oxidase activation in murine neutrophils via formyl peptide receptors.
Bylund J; Samuelsson M; Collins LV; Karlsson A
Exp Cell Res; 2003 Jan; 282(2):70-7. PubMed ID: 12531693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
